Rh Isoimmunization: How a Second Pregnancy Attacks Fetal Blood

What It Is and Why It Matters

Rh isoimmunization occurs when an RhD-negative woman is exposed to RhD-positive red blood cells — almost always fetal cells from an RhD-positive baby — and mounts an IgG antibody response against the RhD (D) antigen. About 15% of people of European ancestry are RhD-negative (lower in African and Asian populations), so the pregnancy setup is common.

The RhD antigen is a transmembrane protein encoded by the RHD gene on chromosome 1; RhD-negative individuals typically have a complete deletion of RHD. Because RhD is highly immunogenic, exposure to even 0.1 mL of RhD-positive blood can trigger sensitization.

• The first sensitizing pregnancy is usually spared — the primary immune response is slow IgM that does not cross the placenta.
• The next RhD-positive pregnancy triggers a rapid, high-titer IgG memory response — and IgG does cross the placenta, attacking fetal cells.

Untreated, it causes hemolytic disease of the fetus and newborn (HDFN), historically a leading cause of fetal and neonatal death.

The Mechanism, Step by Step

The pathophysiology is a textbook type II (antibody-mediated) hypersensitivity reaction unfolding across two pregnancies:

• Fetomaternal hemorrhage: RhD-positive fetal red cells cross into maternal circulation, most often at delivery, but also with miscarriage, ectopic pregnancy, amniocentesis, trauma, or abruption.
• Primary sensitization: The mother's naive B cells recognize RhD and produce IgM first, then class-switch. Memory B cells and anti-D IgG are established — but IgM cannot cross the placenta, so the sensitizing fetus is usually unharmed.
• Anamnestic (secondary) response: In a later RhD-positive pregnancy, small hemorrhages re-expose memory cells, producing high-titer IgG anti-D.
• Placental transfer: IgG crosses via FcRn (neonatal Fc receptor) transcytosis and binds fetal RhD-positive erythrocytes.
• Extravascular hemolysis: Antibody-coated cells are cleared by splenic macrophage Fcγ receptors, causing anemia. The fetus compensates with extramedullary hematopoiesis, releasing nucleated red cells (erythroblastosis fetalis).

Severe anemia leads to high-output heart failure, hepatic congestion, hypoalbuminemia, and generalized edema — hydrops fetalis.

Clinical Presentation and Classic Signs

Because sensitization is silent, the mother herself has no symptoms — the disease is entirely fetal and neonatal.

In the fetus, escalating anemia produces the classic hydropic picture on ultrasound:

• Hydrops fetalis — fluid in ≥2 compartments: ascites, pleural/pericardial effusions, skin edema, and placentomegaly.
• Polyhydramnios and enlarged cardiac silhouette from high-output failure.
• Historically termed erythroblastosis fetalis for the flood of nucleated erythroblasts.

In the neonate, the hallmark is rapid, severe jaundice within the first 24 hours of life — a red flag distinguishing hemolytic from physiologic jaundice. Findings include:

• Hepatosplenomegaly (extramedullary hematopoiesis).
• Pallor from ongoing hemolysis.
• Kernicterus — unconjugated bilirubin crosses the immature blood-brain barrier and deposits in the basal ganglia, causing hypertonia, opisthotonus, a high-pitched cry, and later choreoathetoid cerebral palsy and sensorineural hearing loss.

Diagnosis: Tests, Titers, and Doppler Cutoffs

Diagnosis is a staged workup combining serology with fetal surveillance:

• Type & screen at first prenatal visit: maternal ABO/RhD status plus an antibody screen (indirect Coombs / indirect antiglobulin test) to detect anti-D.
• Titer: a rising or critical maternal titer — commonly ≥1:16 — triggers fetal monitoring. Titers alone don't grade severity but flag risk.
• Middle cerebral artery peak systolic velocity (MCA-PSV) Doppler: the noninvasive gold standard for fetal anemia. A value >1.5 multiples of the median (MoM) for gestational age predicts moderate-to-severe anemia with ~100% sensitivity, having largely replaced serial amniocentesis.
• Amniocentesis (ΔOD450, Liley/Queenan curves): older method measuring bilirubin in amniotic fluid; now mostly historical.
• Cell-free fetal DNA from maternal plasma can noninvasively determine fetal RHD genotype.

In the newborn: a positive direct antiglobulin test (direct Coombs, DAT) confirms antibody-coated RBCs, plus anemia, reticulocytosis, and rising unconjugated bilirubin.

Management and Prevention — Why Each Step Works

Management splits into prevention (the true triumph) and treatment of an already-affected fetus.

Prevention — Rho(D) immune globulin (RhoGAM): a purified anti-D IgG given to unsensitized RhD-negative mothers. It works by antibody-mediated immune suppression — the passive anti-D binds and clears fetal RhD cells before the maternal immune system can mount its own primary response, preventing memory-B-cell formation. Standard dosing: 300 µg at 28 weeks and again within 72 hours of delivery of an RhD-positive infant, plus after any sensitizing event (miscarriage, amniocentesis, trauma). A Kleihauer-Betke test or flow cytometry quantifies large fetomaternal hemorrhage to dose additional RhoGAM.

Treatment of established disease:

• Intrauterine transfusion of RhD-negative, O, irradiated, leukoreduced RBCs into the umbilical vein for severe fetal anemia (MCA-PSV >1.5 MoM).
• Neonatal phototherapy to photoisomerize bilirubin, and exchange transfusion to remove antibody-coated cells and bilirubin, preventing kernicterus.

Distinctions, Mimics, and Do-Not-Miss Pitfalls

Not all HDFN is Rh, and not all fetal hydrops is immune:

• ABO incompatibility (group O mother, A/B infant) is more common but milder — usually just neonatal jaundice, often a weakly positive or negative DAT, and it can affect a first pregnancy. RhoGAM does not prevent it.
• Anti-Kell (anti-K) HDFN is a critical mimic: it causes severe anemia not just by hemolysis but by suppressing fetal erythroid progenitors, so amniotic bilirubin (ΔOD450) underestimates severity — rely on MCA Doppler instead.
• Nonimmune hydrops (parvovirus B19, alpha-thalassemia, cardiac/chromosomal causes) has a negative antibody screen.

Pitfalls:

• Forgetting RhoGAM after any sensitizing event — miscarriage, ectopic, CVS, external cephalic version, abdominal trauma.
• Missing a large fetomaternal hemorrhage that exceeds a single 300 µg dose (each vial covers ~15 mL fetal RBCs / 30 mL whole blood).
• Weak-D (Du) mothers may be mistyped as RhD-negative — careful serology matters.

Rh (anti-D) vs ABO vs anti-Kell hemolytic disease of the fetus and newborn

Feature	Rh (anti-D) HDFN	ABO HDFN	Anti-Kell HDFN
Antibody class	IgG (crosses placenta)	IgG anti-A,B (mostly group O mothers)	IgG anti-K
First pregnancy affected?	Usually spared (needs prior sensitization)	Can affect first pregnancy	Often first pregnancy
Severity	Severe; hydrops, stillbirth	Usually mild neonatal jaundice	Severe; can be profound
Direct Coombs (DAT)	Strongly positive	Weakly/often negative	Positive
Mechanism of anemia	Immune hemolysis of coated RBCs	Mild hemolysis	Hemolysis + erythroid suppression in marrow
Prevention available?	Yes — RhoGAM	No specific prophylaxis	No specific prophylaxis